ateapharma

Discovery & development of breakthrough therapies for COVID-19 patients and severe viral diseases

[ateapharma @ateapharma]

Today, we are excited to announce positive initial data from the Ph2 study evaluating bemnifosbuvir, our oral nucleotide polymerase inhibitor in combination with ruzasvir, an oral NS5A inhibitor, for the treatment of #HepC at #EASLCongress 2024.

https://t.co/5kRXNjSlDo

[ateapharma @ateapharma]

Today, we are pleased to announce enrollment completion in the global Ph3 SUNRISE-3 trial evaluating bemnifosbuvir, our oral nucleotide antiviral, for the treatment of #COVID19. https://t.co/A3EO6mBNMS

[ateapharma @ateapharma]

Former Surgeon General @JeromeAdamsMD explains how we can protect vulnerable seniors and immunocompromised patients by prioritizing new #COVID19 oral antiviral treatments. Read more @statnews: https://t.co/0CB3Yp5vjd

[ateapharma @ateapharma]

Collectively, we can – and must – continue to raise awareness, education and funding to expand #COVID19 treatment options for those most vulnerable and ensure pandemic preparedness. Read more @Politico: https://t.co/jbFXZ12DKF

[ateapharma @ateapharma]

#Atea Pharmaceuticals appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Pharmaceutical research leader brings more than 25 years of drug discovery and development experience from Merck.

https://t.co/K9RSg22utA

[ateapharma @ateapharma]

#Atea 3Q21 update for #AT527 for #COVID19: planned amendment to Ph3 MORNINGSKY protocol, exploratory analyses of infectious virus from Ph2 MOONSONG trial and new in vitro results demonstrating potent activity against COVID #variants, including Delta.

https://t.co/m56vKBD9aC

[ateapharma @ateapharma]

Link to press release below:

https://t.co/wYqkPOB4pT

[ateapharma @ateapharma]

#Atea Pharmaceuticals to present data @ISIRV-WHO Virtual Conference 2021, Oct. 19-21. Data include #AT527 Ph 2 interim results in hospitalized patients w/COVID-19 & Ph 1 results demonstrating AT-527 reaches lungs in healthy volunteers, target organ of #COVID19 infection. $AVIR

[ateapharma @ateapharma]

#Atea Pharmaceuticals is participating in a fireside chat @ Morgan Stanley’s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 2:00 pm ET. A live webcast will be available at the link below $AVIR #pandemic #COVID #AT527 #AT752

https://t.co/6RORbIM1T8

[ateapharma @ateapharma]

#Atea Pharmaceuticals announces publication of data highlighting AT-752’s potent in vitro and in vivo activity against #dengue and other #flaviviruses in Antimicrobial Agents and Chemotherapy #AAC #AT752

https://t.co/uNT6KI5Kb1

[ateapharma @ateapharma]

#Atea 2Q 2021 earnings call reported data from BAL study; #AT-527 is first direct acting antiviral being developed for #COVID-19 that achieved target drug levels in healthy volunteer lungs, key site for COVID-19 infection and #SARS-Cov-2 replication. AT-527 in Ph 3 w/ @Roche.

[ateapharma @ateapharma]

Please join us for a clinical, corporate and financial update on our second quarter 2021 earnings conference call, taking place on August 12 at 4:30pm ET.
#COVID #antiviral #pandemic

https://t.co/I5zZrqBv7b

[ateapharma @ateapharma]

Positive interim results from global Ph 2 trial for AT-527 indicate rapid, sustained antiviral activity against SARS-CoV-2 in hospitalized patients with COVID-19. Atea and Roche are jointly developing AT-527, an oral direct-acting antiviral agent #pandemic
https://t.co/N4mWzqXoWE

[Roche @Roche]

We are thrilled about working with our partner @AteaPharmaceuticals and the potential impact this innovation might have in the fight against the #pandemic! The @NYtimes shines a light on this and other possible treatments to end #covid19 👉 https://t.co/XmKKX4pG3o

[ateapharma @ateapharma]

#Atea Milestone: We achieved a development milestone for AT-527 and expect to receive a $50M payment from Roche. Realization of this milestone brings us one step closer to providing an oral, easily administered #antiviral to fight this #COVID-19 #pandemic. https://t.co/OUQ6jE0XB4

[ateapharma @ateapharma]

Our Senior Management Team expands: we appointed Claudio Avila, MB, BS, Ph.D., as SVP of Medical Affairs. Claudio joins from Gilead where he was Executive Director of U.S. Medical Strategy & Medical Affairs for COVID-19. Welcome to the team, Claudio!
https://t.co/mbLcKCfvsY

[ateapharma @ateapharma]

#Atea milestone: dosed #firstpatient PH 3 #MORNINGSKY - a global multicenter #AT527 trial in mild/moderate COVID-19 pts. MORNINGSKY to enroll 1,400 non-hospitalized adults/adolescents – our goal is to provide an oral antiviral to fight global #pandemic.
https://t.co/Xkq2511FsF

[ateapharma @ateapharma]

.@statnews reported on Atea’s oral antiviral drug candidate #AT527, a potential treatment for #COVID19, in their recent article "Scientists work toward an elusive dream: a simple pill to treat Covid19"
https://t.co/VDfpRlQj7u

[Meg Tirrell @megtirrell]

A pill for #covid19 you could take for 5 days upon diagnosis and be done? A number of antiviral drugs are in development for #covid19. We talked with Dr Fauci and @cispt2 about the hope for these drugs and how they're different:

[ateapharma @ateapharma]

#AT527 PH1 result #croi2021 well-tolerated potential for meaningful uptake in lungs; suggest drug exposure in lungs above level needed to inhibit viral replication. AT-527 targets #SARSCoV2 RNA polymerase responsible for viral RNA replication/transcription
https://t.co/SzlQyOhcMI